• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cell Therapy Catapult, U Birmingham, Cancer Research Technology partner

Cell Therapy Catapult, U Birmingham, Cancer Research Technology partner

January 6, 2016
CenterWatch Staff

The Cell Therapy Catapult, the University of Birmingham and Cancer Research Technology have launched a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumors.

The Cell Therapy Catapult is a U.K. organization dedicated to the growth of the U.K. cell and gene therapy industry by bridging the gap between scientific research and commercialization. Cancer Research Technology is the commercialization arm of Cancer Research U.K.

The new effort is aimed at translating an academic discovery program funded by Cancer Research U.K. and developed by Dr. Steven Lee and Professor Roy Bicknell at the University of Birmingham into a commercially viable cell therapy. The collaborating partners have launched a new company, Chimeric Therapeutics, which will hold all future IP rights to the resultant discoveries.

The project is based on a new generation chimeric antigen receptor T-Cell (CAR-T) immuno-oncology therapy for solid tumors. It involves directing the CAR-T cell toward a new, highly specific marker of tumor angiogenesis, CLEC14a. The therapy will act as a vasculature disruptive agent compromising oxygen supply to the tumors and inhibiting tumor growth. The technology currently is undergoing the final stages of preclinical development, and is planned to enter into clinical trials soon after.

Cancer Research Technology and the university have partnered with the Cell Therapy Catapult to bring their extensive regulatory, clinical, analytical and manufacturing process development expertise into the program, utilizing their experience in developing immunotherapies for cancer. The Cell Therapy Catapult specifically will be involved in the project to accelerate the translation of the academic discoveries made in Birmingham with Cancer Research Technology around CAR-T immunotherapies for solid tumors and the CLEC14a target toward a commercially available cell therapy.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing